计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存,干燥。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
KU 59403 is a potent ATM inhibitor, with IC 50 values of 3 nM, 9.1 μM and 10 μM for ATM , DNA-PK and PI3K , respectively
In Vitro
KU 59403 (1 μM) enhances VP-16 (1 μM) cytotoxicity to a similar extent in HCT116 and HCT116-N7 cells, and in the p53 mutant SW620 cells and human breast cancer cell line, MDAMB-231, sensitisation is 11.9±4.7 and 3.8±1.8-fold respectively. Inhibition of IR-induced ATM activity by KU 59403 (1 μM) is approximately 50% in MDA-MB231 cells and >50% in HCT116 cells that have low ATM expression and activity. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: LoVo, HCT116 and SW620 (human colon cancer), and U2OS (human osteosarcoma) and MDA-MB-231 (human breast cancer) cells. Concentration: 1 μM. Incubation Time: 16 hours. Result: Had at least 1000 times greater specificity for ATM over other members of the PI3K family tested. Enhanced camptothecin cytotoxicity in both cell lines with greater enhancement being observed in the LoVo compared to the SW620 cells. Significantly enhanced the cytotoxicity of fixed concentrations of VP-16 (0.1 and 1 μM) or NSC 123127 (10 or 100 nM) in these cell lines, with greater enhancement of VP-16 in SW620 cells and of NSC 123127 in LoVo cells.
In Vivo
KU59403 with a single daily dose of 12.5 mg/kg causes a significant sensitization . Increasing the dose of KU59403 to 25 mg/kg given twice daily results in the greatest chemo-sensitisation with a 3-fold increase in BMY-40481-induced tumour growth delay in both SW620 and HCT116-N7 xenografts, in the absence of a significantly increased toxicity . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: CD-1 nude mice implanted with SW620 or HCT116-N7 human cancer cell lines at 1×10 7 cells per animal s.c. (n=5 per group) . Dosage: 6, 12.5 and 25 mg/kg. Administration: I.P. twice daily (0 and 4 hours) and 12.5 mg/kg once daily. Result: Treatment with BMY-40481 alone causes a modest tumour growth delay of 4 days (time to RTV4=10.5 days). This delay is extended to 8.5 days when given with KU 59403 at 12.5 mg/kg i.p. twice daily for 5 days and 11.5 days (time to RTV4=18 days) when given with KU 59403 at 25 mg/kg i.p. twice daily for 5 days.
Form:Solid
IC50& Target:IC50: 3 nM (ATM)
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 苯并二噻吩 |
| 亚类(Subclass) | 1,4-苯并二噻吩 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 噻蒽类 |
| 其他上位类(Alternative Parents) | β氨基酸及其衍生物 二芳基硫醚 N-芳基酰胺 二烷基芳胺 吡喃酮及其衍生物 N-甲基哌嗪 苯类化合物 吗啉 乙烯基酰胺 杂芳族化合物 三烷基胺 仲羧酸酰胺 环酮 氮杂环化合物 氧环化合物 二烷基醚 碳氢化合物衍生物 有机氧化物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 1,4-二氮杂环丁烷 - 氨基酸 - 氨基酸或其衍生物 - 芳香族杂多环化合物 - 芳基硫醚 - 氮杂环 - 苯基化合物 - β-氨基酸或其衍生物 - 羰基 - 羧酰胺基 - 羧酸衍生物 - 环酮 - 二烷基醚 - 二烷基芳基胺 - 二芳基硫醚 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - Morpholine - N-烷基哌嗪 - N-芳基酰胺 - N-甲基哌嗪 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 氧杂环 - 氧杂吡嗪烷 - 哌嗪 - 吡喃 - 吡喃酮 - 醛基 - 三元脂肪胺 - 三芳基胺 - 噻吩 - 硫醚 - 乙烯酰胺 |
| 描述(Description) | 该化合物属于有机化合物中的噻吩类。这类有机化合物含有噻吩结构单元。噻吩是一种三环环系,由两个苯环通过1,4-二硫环相连而成。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|